 Genprex, Inc. NASDAQ:GNPX announced that the Safety Review Committee SRC has approved a continuation of the Acclaim-1 Phase 12 clinical trial of the companys lead drug candidate REQORSA in combination with Tagrisso osimertinib to treat late-stage non-small cell lung cancer NSCLC. The approval follows a review of the first cohort of patients in Phase 1 by the SRC, which comprised of three physicians who are principal investigators in the trial, the clinical-stage gene therapy company said. 